Claire Aldridge, Ph.D. serves as Senior Vice President, Chief of Staff and Business Operations at Taysha Gene Therapies, a Dallas-based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund. Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits.
Dr. Aldridge has leveraged her training as a translator, or liaison, between scientists and non-scientists, communicating effectively about the potential of science. Her roles have included technology commercialization; improving patient outcomes through quality based initiatives; working with disease-specific nonprofits; development and venture philanthropy; and biotech and life science investing through venture capital.
Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.